Zara Malik, head of regulatory affairs, LFH discusses companion diagnostics in Europe and the evolving regulatory landscape.
Companion diagnostics (CDx) are becoming a key part of personalised medicine, enabling healthcare providers match patients with the most effective treatments and therapies. As the demand for precision treatments grow, so does the importance of having robust and reliable diagnostics that guide clinical decisions.